These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31815880)

  • 1. CLINICAL CHARACTERISTICS AND OUTCOME OF POSTERIOR CYSTOID MACULAR DEGENERATION IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Mohabati D; Hoyng CB; Yzer S; Boon CJF
    Retina; 2020 Sep; 40(9):1742-1750. PubMed ID: 31815880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study.
    Silva RM; Ruiz-Moreno JM; Gomez-Ulla F; Montero JA; Gregório T; Cachulo ML; Pires IA; Cunha-Vaz JG; Murta JN
    Retina; 2013 Feb; 33(2):309-15. PubMed ID: 23095766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy.
    Nicolò M; Zoli D; Musolino M; Traverso CE
    Am J Ophthalmol; 2012 Mar; 153(3):474-480.e1. PubMed ID: 22019224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea.
    van Dijk EHC; Dijkman G; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2029-2035. PubMed ID: 28674835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microperimetric changes and fixation stability status after half-dose photodynamic therapy for chronic central serous chorioretinopathy.
    Gulkas S; Sahin O
    Eur J Ophthalmol; 2020 Sep; 30(5):1053-1060. PubMed ID: 31256613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BASELINE SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI AS A PREDICTOR OF VISUAL OUTCOME AND RECURRENCE FOR CENTRAL SEROUS CHORIORETINOPATHY.
    Lee H; Lee J; Chung H; Kim HC
    Retina; 2016 Jul; 36(7):1372-80. PubMed ID: 26702841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy.
    van Rijssen TJ; van Dijk EHC; Dijkman G; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1395-1402. PubMed ID: 29732468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term Visual Outcomes and Causes of Vision Loss in Chronic Central Serous Chorioretinopathy.
    Mrejen S; Balaratnasingam C; Kaden TR; Bottini A; Dansingani K; Bhavsar KV; Yannuzzi NA; Patel S; Chen KC; Yu S; Stoffels G; Spaide RF; Freund KB; Yannuzzi LA
    Ophthalmology; 2019 Apr; 126(4):576-588. PubMed ID: 30659849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SEROUS MACULAR DETACHMENT IN BEST DISEASE: A Masquerade Syndrome.
    Zatreanu L; Freund KB; Leong BCS; Yu HG; Teke MY; Yzer S; Sadda SR; Sarraf D
    Retina; 2020 Aug; 40(8):1456-1470. PubMed ID: 31613838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Half-fluence photodynamic therapy in acute central serous chorioretinopathy.
    Smretschnig E; Ansari-Shahrezaei S; Moussa S; Glittenberg C; Krebs I; Binder S
    Retina; 2012; 32(10):2014-9. PubMed ID: 22466482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy.
    Gawęcki M; Jaszczuk-Maciejewska A; Jurska-Jaśko A; Kneba M; Grzybowski A
    BMC Ophthalmol; 2019 Jul; 19(1):160. PubMed ID: 31345183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optical coherence tomography angiography findings in cystoid macular degeneration associated with central serous chorioretinopathy.
    Sahoo NK; Mishra SB; Iovino C; Singh SR; Munk MR; Berger L; Peiretti E; Chhablani J
    Br J Ophthalmol; 2019 Nov; 103(11):1615-1618. PubMed ID: 30602447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol.
    Breukink MB; Mohr JK; Ossewaarde-van Norel A; den Hollander AI; Keunen JE; Hoyng CB; Boon CJ
    Acta Ophthalmol; 2016 Mar; 94(2):187-97. PubMed ID: 26670630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
    Smretschnig E; Ansari-Shahrezaei S; Hagen S; Glittenberg C; Krebs I; Binder S
    Retina; 2013 Feb; 33(2):316-23. PubMed ID: 23314238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Multicenter Study on the Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy.
    Lai FH; Ng DS; Bakthavatsalam M; Chan VC; Young AL; Luk FO; Tsang CW; Brelén ME
    Am J Ophthalmol; 2016 Oct; 170():91-99. PubMed ID: 27519561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy.
    Bae SH; Heo JW; Kim C; Kim TW; Lee JY; Song SJ; Park TK; Moon SW; Chung H
    Am J Ophthalmol; 2011 Nov; 152(5):784-92.e2. PubMed ID: 21742303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy.
    Nicoló M; Eandi CM; Alovisi C; Grignolo FM; Traverso CE; Musetti D; Cardillo Piccolino F
    Am J Ophthalmol; 2014 May; 157(5):1033-7. PubMed ID: 24487046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of photodynamic therapy in steroid-associated chronic central serous chorioretinopathy: a case-control study.
    Breukink MB; Mohabati D; van Dijk EH; den Hollander AI; de Jong EK; Dijkman G; Keunen JE; Hoyng CB; Boon CJ
    Acta Ophthalmol; 2016 Sep; 94(6):565-72. PubMed ID: 27149889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.
    Sheptulin V; Purtskhvanidze K; Roider J
    Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2027-2034. PubMed ID: 30097783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OCT Risk Factors for 3-Year Development of Macular Complications in Eyes With "Resolved" Chronic Central Serous Chorioretinopathy.
    Borrelli E; Battista M; Sacconi R; Gelormini F; Querques L; Grosso D; Vella G; Bandello F; Querques G
    Am J Ophthalmol; 2021 Mar; 223():129-139. PubMed ID: 33342759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.